Updated:
Olima Ventures
Olima Ventures is an investment firm based in New York, New York. It focuses on early-stage companies in biotech, B2B, distributed systems, and enterprise...
Olima Ventures
Olima Ventures is an investment firm based in New York, New York. It focuses on early-stage companies in biotech, B2B, distributed systems, and enterprise software sectors. The firm invests in 51 startups, including Vistapath, a company in advanced rocket and spacecraft manufacturing.
General information
Firm type
Venture Capital
Year founded
2009
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Vijay
Founder & Investor
Sector focus
Frequently asked questions
Who runs investment decisions at Olima Ventures?
Vijay, the sole named principal, makes all investment decisions. He describes himself as an engineer, entrepreneur, and investor. No other investment professionals, partners, or investment committee members are disclosed. This single-decision-maker structure means sourcing, diligence, and portfolio support all route through one person.
What investment stages does Olima Ventures target?
Olima invests predominantly at the seed stage (per firm website). Roughly 70% of disclosed rounds are tagged as Seed or Pre-seed, with the remainder split across Angel and Series A. The firm occasionally participates in Series B rounds, as with Eigen and Canary Technologies, but does not lead later-stage deals.
Which sectors make up the bulk of Olima's portfolio?
The portfolio concentrates in biotech (BigHat Biosciences, Venostent, Arda, Eigen, Vistapath, Condor), enterprise software and developer tools (Deel, Heroku, Materialize, Orkes, Plasmic, Kaskada), and fintech (Unit21, Lenkie, XCLAIM). Smaller allocations exist in consumer (Wish, ROOM), education (Awari, Wise), and frontier tech (SBX Robotics, Antithesis).
Does Olima Ventures participate in follow-on rounds?
Olima does occasionally participate in follow-on rounds, as seen with nura (Seed and Series A), Seed & Spark (Angel and Series A), and Italic (Seed and Series A). However, follow-on behavior is not systematic, and many portfolio companies receive only a single disclosed check from the firm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: